MENU
ABBV
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

ABBVIE (ABBV) Ownership - Who owns ABBVIE?

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta)... Show more

A.I.Advisor
Nov 08, 2026

What Is AbbVie (ABBV)? Company Overview, Business Model and Market Position

Key Takeaways

  • AbbVie (ABBV) is a global, research-based biopharmaceutical company headquartered in North Chicago, Illinois.
  • It was created in January 2013 when it was spun off from Abbott Laboratories (ABT).
  • The company focuses on immunology, oncology, neuroscience, aesthetics, and eye care, and markets products in more than 175 countries.
  • Its best-known brands include Humira, Skyrizi, Rinvoq, and Botox, with Skyrizi and Rinvoq now driving growth as Humira faces biosimilar competition.
  • AbbVie generated worldwide net revenues of roughly $56.3 billion in 2024 and employs approximately 55,000 people.

Introduction

AbbVie Inc. is one of the world's largest research-based biopharmaceutical companies, best known for developing and selling medicines that treat chronic and complex conditions such as autoimmune diseases, cancer, and neurological disorders. Investors follow ABBV because it combines a diversified portfolio of established blockbuster drugs with a deep pipeline of experimental treatments. Its company overview and financial profile make it a prominent name in the global healthcare sector.

Company History and Headquarters

AbbVie was formed on January 1, 2013, when diversified healthcare group Abbott Laboratories separated its research-based pharmaceutical business into a new, independent company. The spinoff allowed the faster-growing branded drug operations to trade under their own identity while Abbott retained its diversified medical products, diagnostics, and nutrition businesses. AbbVie is headquartered in North Chicago, Illinois, and its shares trade on the New York Stock Exchange.

Business Model and Core Products

AbbVie's business model centers on discovering, developing, manufacturing, and commercializing innovative medicines, then generating revenue by selling them to wholesalers, distributors, pharmacies, hospitals, and government agencies around the world. The company's most important therapeutic areas include:

  • Immunology: Treatments for autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Key brands are Humira, Skyrizi, and Rinvoq.
  • Oncology: Cancer therapies such as Venclexta and Imbruvica, as well as antibody-drug conjugates like Elahere following the ImmunoGen acquisition.
  • Neuroscience: Psychiatric and neurological medicines including Vraylar and migraine treatments Ubrelvy and Qulipta.
  • Aesthetics: Cosmetic and therapeutic products led by Botox and the Juvederm filler collection, acquired through the 2020 purchase of Allergan.
  • Eye care: A smaller but complementary portfolio of specialty products.

Revenue Sources and Market Position

For years, Humira was the company's dominant revenue engine and at one point ranked among the world's best-selling drugs. Because Humira lost U.S. market exclusivity in 2023, biosimilar competition has steadily reduced its sales. AbbVie's newer immunology medicines, Skyrizi and Rinvoq, have taken over as the primary growth drivers. In 2024, Skyrizi generated approximately $11.7 billion in net revenues and Rinvoq roughly $6.0 billion, while Humira declined to about $9.0 billion as cheaper biosimilars gained share. This transition is central to understanding AbbVie's current market position and long-term strategy.

Why Investors Follow ABBV

AbbVie attracts investor attention for several reasons. The company has a strong track record of commercializing blockbuster medicines and has demonstrated an ability to refresh its portfolio through internal research and targeted acquisitions, including the transformative Allergan deal in 2020. Its diversified revenue base spans immunology, oncology, neuroscience, and aesthetics, reducing dependence on any single product or disease area. AbbVie also generates substantial operating cash flow and has historically returned capital to shareholders through dividends and share repurchases, which makes it relevant to income-focused and long-term investors alike.

Risks and Important Considerations

Investors should weigh several factors before investing in AbbVie. The most significant near-term challenge is the erosion of Humira sales as biosimilar competitors enter the market, which places pressure on the company to offset those losses with newer products. Like all pharmaceutical companies, AbbVie faces the risk that clinical trials fail, regulatory approvals are delayed, or drugs lose patent protection. Pricing and reimbursement pressures from governments and private payers can also constrain revenue, particularly outside the United States. Finally, the business carries industry-level risks related to competition, litigation, and the inherent uncertainty of drug development.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Whether you are researching large-cap pharmaceutical names like AbbVie or exploring other sectors, the AI Screener offers a streamlined way to narrow the field.

Conclusion

AbbVie is a diversified biopharmaceutical leader whose portfolio spans some of the most important treatment areas in modern medicine. What makes the company distinctive is its ability to transition from a single blockbuster product into a broader, multi-franchise growth platform, supported by a robust pipeline and selective acquisitions. As it navigates the post-Humira era, AbbVie remains a closely watched name for investors seeking exposure to the global healthcare and pharmaceutical sector.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Profile

Industry
Pharmaceuticals Major
Address
1 North Waukegan Road
Phone
+1 847 932-7900
Employees
57000
Web
https://www.abbvie.com

Details

Group
Domestic Stock Funds
Category
Pharmaceuticals
Capitalization
514.78B
P/E Ratio
82.29
Total Cash
6.57B
Projected Growth
0.54
Total Debt
70.82B
Revenue
64.39B
Risk (Beta)
0.03
Dividend Yield
0.02
Total Cash/Share
3.72
Total Debt/Equity
314.07
Revenue/Share
36.30 USD as % of share price
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a research-based pharmaceutical company

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
1 North Waukegan Road
Phone
+1 847 932-7900
Employees
57000
Web
https://www.abbvie.com
Who owns ABBVIE? ABBV symbol Ownership - Tickeron.com